Cassava Sciences Inc (SAVA)
25.84
-0.37
(-1.41%)
USD |
NASDAQ |
Nov 04, 16:00
26.00
+0.16
(+0.62%)
After-Hours: 20:00
Cassava Sciences Cash from Investing (Quarterly): -0.029M for June 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -0.029M |
| March 31, 2024 | 0.00 |
| December 31, 2023 | -0.041M |
| September 30, 2023 | -0.022M |
| June 30, 2023 | 0.006M |
| March 31, 2023 | -0.357M |
| December 31, 2022 | 0.335M |
| September 30, 2022 | -1.156M |
| June 30, 2022 | -1.466M |
| March 31, 2022 | -0.425M |
| December 31, 2021 | -0.10M |
| September 30, 2021 | -22.04M |
| June 30, 2021 | -0.073M |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.26M |
| March 31, 2020 | 0.10M |
| December 31, 2019 | 0.00 |
| September 30, 2019 | 0.00 |
| June 30, 2019 | 0.00 |
| March 31, 2019 | -0.018M |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| Date | Value |
|---|---|
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 2.101M |
| December 31, 2016 | -1.544M |
| September 30, 2016 | -0.625M |
| June 30, 2016 | 1.50M |
| March 31, 2016 | -1.497M |
| December 31, 2015 | 0.90M |
| September 30, 2015 | 0.051M |
| June 30, 2015 | 1.051M |
| March 31, 2015 | -2.194M |
| December 31, 2014 | 1.101M |
| September 30, 2014 | -0.851M |
| June 30, 2014 | 1.001M |
| March 31, 2014 | -0.079M |
| December 31, 2013 | 0.051M |
| September 30, 2013 | 0.001M |
| June 30, 2013 | 1.501M |
| March 31, 2013 | 4.103M |
| December 31, 2012 | -2.605M |
| September 30, 2012 | 10.52M |
| June 30, 2012 | 7.005M |
| March 31, 2012 | 2.705M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-22.04M
Minimum
Sep 2021
0.335M
Maximum
Dec 2022
-1.316M
Average
-0.022M
Median
Sep 2023
Cash from Investing (Quarterly) Benchmarks
| Bristol-Myers Squibb Co | -219.00M |
| Eli Lilly and Co | -4.005B |
| Seelos Therapeutics Inc | -- |
| Biomarin Pharmaceutical Inc | -16.16M |
| EyePoint Pharmaceuticals Inc | -160.40M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -18.24M |
| Cash from Financing (Quarterly) | 101.39M |
| Free Cash Flow | -86.31M |
| Free Cash Flow Per Share (Quarterly) | -0.3954 |
| Free Cash Flow Yield | -7.66% |